Pharma procurement teams don’t buy “a drug.” They buy a total outcome—across contracts, supply risk, forecasting accuracy, inventory carrying costs, patient access timelines, and the operational drag of exceptions.
That’s the uncomfortable truth behind…
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams Read Post »
Pharma executives don’t lose in Eurasia because they “missed a filing.”
They lose because they misunderstood the system.
Drug patents in Eurasia aren’t just a legal checklist item—they’re a moving target shaped by jurisdictional quirks, enforcement rea…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Wish They Had Earlier
In pharma, speed is a competitive advantage—until it isn’t.
A launch timeline that looks perfect on a Gantt chart can collapse overnight when a single patent right, …
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you already know the headline numbers: patent terms, regulatory exclusivities, and “up to” …
GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry is used to hype cycles. A new model drops. A few demos go viral. Then the real question arrives: Does it change anything that matters—timeli…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Europe’s drug patent clock is ticking—and most people misunderstand where it actually stops.
If you think “20 years from filing” is the whole story, you’re already behind. In Europe, the timeline that determines when generics and biosimilars can ente…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
AI is quietly becoming the new “KOL” in pharma—and most companies aren’t tracking it.
For years, drugmakers have mapped influence the old way: key opinion leaders, conference circuits, advisory boards, and the slow grind of peer-reviewed credibility. B…
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »
Most pharma teams wait until the patent is already dying. That’s why they miss the money.
In drug development, timing is everything—but in licensing, timing is everything squared. The closer a product gets to patent expiry, the more value concentrates …
Drug patent expiry isn’t a single date—it’s a moving target across jurisdictions, regulatory regimes, and legal timelines. And if your portfolio planning still treats it like a one-size-fits-all calendar event, you’re likely making decisions on incompl…
Generic entry is inevitable—unless you build a moat that can’t be copied.
Most investors and operators obsess over the obvious: composition-of-matter patents, branded label exclusivity, and blockbuster timelines. But in the real world, generics don’t…